Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10240551 | 0.85 | TRPA1 (0.43) | TAAR1HTR1AHTR1DHTR1BBACE1 | |
| SCHEMBL2007285 | 0.85 | LOXL2 (0.48) | TAAR1LOXL2CYP2A6IDO1AGXT | |
| SCHEMBL1695325 | 0.83 | CSNK2A1 (0.45) | TAAR1LOXL2BACE1KDM4CCSNK2A2 | |
| SCHEMBL15308657 | 0.81 | TRPA1 (0.40) | TAAR1HTR1AHTR1DHTR1BBACE1 | |
| SCHEMBL6563067 | 0.81 | TAAR1 (0.52) | TAAR1HTR1ABACE1CYP1A2CYP2A6 | |
| SCHEMBL28098160 | 0.80 | TAAR1 (0.44) | TAAR1HTR1AHTR1DHTR1BLOXL2 | |
| SCHEMBL18235903 | 0.80 | LMNA (0.38) | HTR1AHTR1DHTR1BLOXL2BACE1 | |
| SCHEMBL24822460 | 0.79 | TRPA1 (0.39) | TAAR1HTR1AHTR1DHTR1BBACE1 | |
| SCHEMBL22754128 | 0.79 | TRPA1 (0.39) | TAAR1HTR1AHTR1DHTR1BBACE1 | |
| SCHEMBL2948434 | 0.79 | CYP4F2 (0.40) | TAAR1LOXL2IDO1AGXTKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385065-B2 | Antibacterial compounds | REDX PHARMA PLC (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-06-08 | — | — | US | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-12 | — | — | US | disclosed |
| US-7592331-B2 | Macrocyclic factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | ABCC1, SLC11A2, NQO2 | TAAR1 4459/4885HTR1A 4768/4885HTR1D 4807/4885 |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | TAAR1 269/4885HTR1A 995/4885HTR1D 1346/4885 |
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | TAAR1 363/4885HTR1A 1446/4885HTR1D 1746/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | TAAR1 2904/4885HTR1A 1245/4885HTR1D 2434/4885 |
| US-20100056582-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | TAAR1 363/4885HTR1A 1446/4885HTR1D 1746/4885 |
| US-20090281139-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | TAAR1 4325/4885HTR1A 2242/4885HTR1D 3364/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | TAAR1 4325/4885HTR1A 2242/4885HTR1D 3364/4885 |
| US-10385065-B2 | Antibacterial compounds | ABCC1, SLC11A2, NQO2 | TAAR1 4459/4885HTR1A 4768/4885HTR1D 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.